Video

Dr Prithviraj Bose Discusses Identifying Progression in Myelofibrosis

There are formal criteria to identify progression in myelofibrosis, but patients can progress in many different ways, said Prithviraj Bose, MD, of MD Anderson Cancer Center.

There are formal criteria to identify progression in myelofibrosis, but patients can progress in many different ways, said Prithviraj Bose, MD, of MD Anderson Cancer Center.

How do you identify progression in myelofibrosis?

Essentially there are the IWG-MRT [International Working Group-Myeloproliferative Neoplasms Research and Treatment] 2013 criteria that are kind of formal criteria for progression, but those are really to do with the spleen progression and to do with leukemic transformation, and pretty much that’s it.

However, in practice, a patient can progress in many ways. You can have the spleen grow; you can have symptoms worsen; you can have blood counts worsen, by which I mean more anemia, more thrombocytopenia; you can have the white blood cell count go up; and of course you can have the blasts go up and end up in accelerated or blastic phase, which is really the same as leukemic transformation.

So, it can be any of these things or more than one in combination, because you know patients don’t always progress in just one dimension.

Related Videos
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo